Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling

Experimental Hematology

Volumn 35, Issue 1, 2007, Pages 75.e1-75.e11

  Shen, Jing ^a   Tai, Yan Chin ^a   Zhou, Jianbiao ^a   Stephen Wong, Ching Ho ^a   Cheang, Pek Tan S ^b   Fred Wong, Wai Shiu ^b   Xie, Zhigang ^a   Khan, Matiullah ^b   Han, Jin Hua ^b   Chen, Chien Shing ^a,b,c  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN KINASE PIM 1; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN HL 60; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; XENOGRAFT;

ARA;

EID: 33845753470     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.09.007     Document Type: Article

References (32)

1. Smith M., Barnett M., Bassan R., Gatta G., Tondini C., and Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50 (2004) 197-222
2. Jemal A., Tiwari R., Murray T., et al. Cancer statistics. CA Cancer J Clin 54 (2004) 8-29
3. Spinozzi F., Pagliacci M., Migliorati G., et al. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18 (1994) 431-439
4. Traganos F., Ardelt B., Halko N., Bruno S., and Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52 (1992) 6200-6208
5. Li W., and Weber G. Synergistic action of tiazofurin and Gen on growth inhibition and differentiation of K-562 human leukemic cells. Life Sci 63 (1998) 1975-1981
6. Hirano T., Gotoh M., and Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci 55 (1994) 1061-1069
7. Khan M., Ng A., Shen J., Chen C., and Ishii S. Genistein promotes apoptosis, differentiation and cell cycle arrest in all trans retinoic acid (ATRA) sensitive and resistant acute promyelocytic leukemia cells. Blood 104 (2004) 2524
8. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., and Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77 (1991) 1080-1086
9. Gallagher R., Collins S., Trujillo J., et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54 (1979) 713-733
10. Koeffler H.P., and Golde D.W. Human myeloid leukemia cell lines: a review. Blood 56 (1980) 344-350
11. Ogura M., and Hamaguchi M. [Coagulation and fibrinolytic system of macrophages]. Nippon Rinsho 47 (1989) 545-549
12. Tsuchiya S., Kobayashi Y., Goto Y., et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 42 (1982) 1530-1536
13. Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., and Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77 (1991) 2031-2036
14. Chou T., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
15. Honma Y., Ishii Y., Sassa T., and Asahi K. Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. Leuk Res 27 (2003) 1019-1025
16. Jing Y., Wang L., Xia L., et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97 (2001) 264-269
17. Shaik M., Jackson T., and Singh M. Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. J Pharm Pharmacol 55 (2003) 819-825
18. Estey E. Therapeutic options for acute myelogenous leukemia. Cancer 92 (2001) 1059-1073
19. Cui H., Na X., Song D., and Liu Y. Blocking effects of genistein on cell proliferation and possible mechanism in human gastric carcinoma. World J Gastroenterol 11 (2005) 69-72
20. Yu Z., Li W., and Liu F. Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Lett 215 (2004) 159-166
21. Hewitt A., and Singletary K. Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model. Cancer Lett 192 (2003) 133-143
22. Oki T., Sowa Y., Hirose T., Takagaki N., et al. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Lett 557 (2004) 55-59
23. Gong L., Li Y., Nedeljkovic-Kurepa A., and Sarkar F. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 22 (2003) 4702-4709
24. Mohammad R., Al-Katib A., Aboukameel A., Doerge D., Sarkar F., and Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2 (2003) 1361-1368
25. Alhasan S., Aranha O., and Sarkar F. Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin Cancer Res 7 (2001) 4174-4181
26. Su S., Yeh T., Chuang W., et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 69 (2005) 307-318
27. Scholar E., and Toews M. Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein. Cancer Lett 87 (1994) 159-162
28. Buchler P., Reber H., Buchler M., Friess H., Lavey R., and Hines O. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 100 (2004) 201-210
29. Akiyama T., Ishida J., Nakagawa S., et al. Genistein a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262 (1987) 5592-5595
30. Okura A., Arakawa H., Oka H., Yoshinari T., and Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 157 (1988) 183-189
31. Grandage V.L., Gale R.E., Linch D.C., and Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19 (2005) 586-594
32. Yin B., Morgan K., Hasz D.E., et al. Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 20 (2005) 151-154